drugset / Trial / NCT00005985

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

NCT00005985

Phase 2 Completed 213 enrolled Masonic Cancer Center, University of Minnesota
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: This phase II trial is studying how well giving filgrastim together with chemotherapy and peripheral stem cell transplant works in treating patients with Hodgkin's lymphoma or non-Hodgkin's lymphoma.

Timeline

Start
2000-08
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Cytarabine Small molecule Intravenous
Subject Dexamethasone Small molecule Intravenous
Subject Etoposide Small molecule Intravenous
Subject Mitoxantrone Small molecule Intravenous
Subject carmustine Small molecule Intravenous
Subject filgrastim Protein / enzyme biologic Subcutaneous

Indications